Balancing the scales: An inclusive framework for equity in Multi-Cancer Early Detection

Introduction 

Multi-cancer early detection (MCED) tests represent a promising advancement in cancer screening, offering the potential to detect multiple cancers through minimally invasive methods. While these tests hold great promise for improving early detection and patient outcomes, it is imperative to address equity considerations to ensure fair access and outcomes for all individuals.

Expanding Cancer Screening 

Cancer continues to be a leading cause of mortality, underscoring the importance of effective screening strategies. While current screening methods focus on specific cancers, a significant number of cancer-related deaths occur in cancers lacking established screening protocols. Initiatives like the Cancer Moonshot aim to transform cancer screening by developing more comprehensive and accurate approaches, including in-depth understanding of liquid biopsy techniques.

The Promise of MCED Tests 

Liquid biopsy methods offer a non-invasive means of detecting cancer by analysing components released by tumors into bodily fluids, primarily blood. MCED tests have the potential to complement existing screening methods and identify cancers without established screening guidelines. Early research, such as the PanSeer and DETECT-A studies, has shown promising results in detecting cancer signals in individuals without prior cancer diagnoses.

Key Equity Considerations 

1. Diverse Clinical Trial Representation: Ensuring diverse enrollment in MCED trials to assess efficacy across various demographic groups.
2. Insurance Coverage: Advocating for inclusive insurance coverage to make MCED tests accessible to all, regardless of financial status.
3. Diagnostic Follow-Up Testing: Expanding coverage for necessary follow-up tests post-MCED screening to eliminate financial barriers to care.
4. Meaningful Access: Extending access beyond insurance coverage through partnerships with community health systems.
5. Navigation Services: Providing support for patients to navigate post-MCED testing healthcare pathways effectively.
6. Education and Outreach: Developing comprehensive educational materials to inform the public about MCED tests’ benefits and implications.
7. Building Community Trust: Fostering trust through community partnerships and transparent communication efforts.
8. Diverse Workforce: Promoting diversity in decision-making teams to ensure equitable development and dissemination of MCED tests.
9. System Preparedness: Addressing potential system-level burdens resulting from increased demand for MCED testing.

Conclusion 

Prioritising equity in the development and deployment of MCED tests is essential for creating a healthcare landscape that is inclusive and accessible to all. By integrating these equity considerations, stakeholders can work towards a more equitable and effective approach to multi-cancer early detection.